AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) Delayed: 263.96 -0.06 (0.02%)
Previous Close $264.02    52 Week High $68.12 
Open $263.29    52 Week Low $50.71 
Day High $266.34    P/E 57.26 
Day Low $262.44    EPS $4.61 
Volume 8,176,594